专注于罕见疾病和孤儿病治疗的生物制药公司Mirum Pharmaceuticals, Inc.（股票代码：MIRM）今日盘中股价大涨8.78%，引发市场广泛关注。该公司主要产品Livmarli是一种新型口服IBAT抑制剂，用于治疗Alagille综合征患者的胆汁淤积性瘙痒症。
尽管Mirum Pharmaceuticals最近的财报显示净亏损8794万美元，每股亏损1.85美元，但公司营业收入达到3.37亿美元，毛利2.55亿美元，显示出强劲的销售增长潜力。值得注意的是，在参与评级的10家机构中，100%的券商给予买入建议，反映出分析师对公司前景的乐观态度。
与此同时，生物技术行业整体呈现下跌趋势，跌幅为3.34%。在这一背景下，Mirum Pharmaceuticals的强劲表现更显突出。公司专注于开发治疗胆汁淤积性肝病的创新药物，如用于治疗PFIC和ALGS的Maralixibat，以及针对成年胆汁淤积性肝病患者的volixibat，这些产品线有望为公司带来持续增长动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.